-
ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
-
ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data
-
Network for parallel gamma synchronizations during upper limb movement
-
Neural correlates of minor hallucinations in Parkinson’s disease: A multimodal imaging study
-
Neural correlates of movement sequence kinematics in substantia nigra dopaminergic cells
-
Neural Correlates Underlying Reward Processing and Decision-Making in Impulse Control Disorder in Parkinson´s Disease
-
Neuroactive steroids reverse the dopaminergic neurotransmission defectiveness in chronic hepatic (HE) encephalopathy: a possible involvement in HE related parkinsonism
-
Neuroanatomical correlates of depressive symptoms in newly diagnosed Parkinson’s disease patients
-
Neurodegenerative biomarker abnormality frequency in idiopathic REM sleep behavior disorder
-
Neuroferritinopathy pedigree in 2 families from India
-
Neurofilament light chain levels in cerebrospinal fluid do not discriminate between patients with prion disease and mimics
-
Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson’s disease and multiple system atrophy
-
Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms
-
Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review
-
Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration
-
Neurological examination of motor Functional Neurological Disorders: an evidence-based review towards the development of consensus guidelines from the Committee on Research of the ANPA
-
Neurological worsening in patients undergoing treatment for Wilson disease: Frequency, causes and outcomes.
-
Neuromelanin Magnetic Resonance Imaging of the Substatia Nigra in LRRK2 -related Parkinson’s disease
-
Neuroprotection and Alleviation of Parkinsonian Phenotypes by Ayurvedic Herbs
-
Neuroprotection of indole-derivative compound NC001-8 in Parkinson disease cell model by regulatory of NRF2 pathway
-
Neuroprotective effect of α-Mangostin in restoration mitochondrial function in MPTP-Induced Parkinson’s disease in mice
-
Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes
-
Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease
-
Neuroprotective propensity of PTUPB, a dual inhibitor of sEH and COX-2 against rotenone induced neurotoxicity in cell line and Drosophila model of Parkinson disease
-
Neuropsychiatric and Cognitive Predictors of Early Diagnosis of Progressive Supranuclear Palsy
-
Neuropsychiatric symptoms after bilateral stimulation in Parkinson’s disease: subthalamic nucleus versus globus pallidus internus.
-
Neuropsychological predictors of patient-reported cognitive outcomes following deep brain stimulation
-
Neuropsychological profile of corticobasal degeneration, progressive supranuclear palsy and frontotemporal dementia patients
-
Neuroticism and depression is associated with impulse control disorder in Parkinson’s disease: a controlled study
-
Neurotological Findings in Sporadic Ataxia
-
New device HANABI (HANdai Amyloid Burst Inducer) is a rapid and sensitive detecting system of α synuclein fibril in CSF from Parkinson’s disease patients
-
New method to evaluate new motor skill learning
-
New XK deletion associated with McLeod syndrome
-
Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia
-
Noladin ether attenuates MPTP -induced motor deficit by abrogating pro-inflammatory cytokines and striatal neurochemical alterations in rats
-
Non motor symptoms in patients with Writer’s cramp
-
Non-Invasive Assessment of Swallowing and Respiration Coordination in Early Parkinson’s Disease
-
Non-motor features of p.A53T α-synuclein mutation carriers compared to sporadic Parkinson’s disease in a PPMI cohort .
-
Non-motor symptom burden is associated with thalamic atrophy in Parkinson’s disease
-
Non-motor symptoms and gender differences in multiple system atrophy
-
Non-motor symptoms in a cross section of PD patients with varying degrees of smell loss
-
Non-motor symptoms in ACDY5-associated disease
-
Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients
-
Non-motor symptoms in Parkinsons’s disease patients treated with levodopa-carbidopa intestinal gel infusion- the follow up study
-
Non-motor symptoms in patients with Parkinson’s disease, essential tremor and both diseases – a group comparison
-
Non-motor symptoms in the first neurology consultation in Cali – Colombia
-
Non-Progressive Coreoatethosis Secondary to Infantile Necrotizing Encephalopathy Mimicking Leigh Disease.
-
Noninvasive cerebellar stimulation for adults with cervical dystonia
-
NonMotor and Motor symptoms in Idiopathic Parkinson´s Disease and Secondary parkinsonism The “Parkinsons Well-Being MapTM” – a useful instrument in Clinical praxis.
-
Nonmotor disorders in Parkinsonism: Experience in Kyrgyz Republic
-
Nonpharmacological therapies for sleep disturbances in Parkinson’s disease patients: A Systematic review
-
Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?
-
Novel Programming Strategy to Overcome Loss of Efficacy in Essential Tremor
-
Novel TUBB4A variants in idiopathic dystonia
-
NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders
-
NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy
-
Number and characteristics of people who requested the Portuguese Version of the European Physiotherapy Guideline for Parkinson’s Disease: a one-year follow-up
-
Nutritional status and changes in body weight in patients with multiple system atrophy
2017 International Congress
June 4-8, 2017. Vancouver, BC.